InsidersTradesSigma
CROSSJECT Stock: price and management transactions · France · AMF
Follow the CROSSJECT share price and the full management transaction log of the company, a listed issuer based in France. Shares are listed on FR FR, under the supervision of AMF. Operating in the Healthcare & Pharma sector, CROSSJECT has logged 47 reports. Market capitalisation: €117.1m. The latest transaction was filed on 2 July 2025 (Souscription). Among the most active insiders: Eric Nemeth. The full history is free.
47
Insider Decl.
0
Thresholds
€1m
11 ops.
Buy Volume
€182
3 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate CROSSJECT Strong Buy (bullish), based on 2 analysts. Average price target: €4.40.
57Σ signal
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Last declaration on 2 July 2025
Declarations47 total
13,386 shares@ €1.4010.0% of flowActionHors plateforme de négociation2025DD1045604
3,215 shares@ €1.402.4% of flowActionHors plateforme de négociation2025DD1045061
1,182 shares@ €1.400.9% of flowActionHors plateforme de négociation2025DD1045062
15,871 shares@ €1.4011.9% of flowActionHors plateforme de négociation2025DD1043795
1,075 shares@ €1.400.8% of flowActionHors plateforme de négociation2025DD1043815
300,000 shares0ActionEuronext Growth Paris2025DD1021709
Ideal exit: 16 Nov 2025 (T+270)
1,262,626 shares@ €0.378810.7% of flowOption d'achatEuronext Paris2024DD1011409
1,262,626 shares@ €1.601245.4% of flowActionEuronext Paris2024DD1011407
20,000 shares0ActionEuronext Paris2024DD982992
Ideal exit: 21 Mar 2025 (T+270)
20,000 shares0ActionEuronext Paris2024DD982993
Ideal exit: 21 Mar 2025 (T+270)
130,000 shares0ActionEuronext Growth Paris2024DD982585
Ideal exit: 17 Mar 2025 (T+270)
10,979 shares@ €1.84810.9% of flowActionHors plateforme de négociation2024DD971458
10,074 shares@ €1.8480.5% of flowActionEuronext Growth Paris2024DD970268
1,058,617 shares@ €1.84843.9% of flowActionEuronext Growth Paris2024DD970211
25,882 shares@ €1.84825.6% of flowActionHors plateforme de négociation2024DD970089
10,357 shares@ €1.84810.2% of flowActionHors plateforme de négociation2024DD970091
5,536 shares@ €1.8485.5% of flowActionEuronext Growth Paris2024DD970037
Ideal exit: 3 Mar 2025 (T+270)
3,504 shares@ €1.8483.5% of flowActionHors plateforme de négociation2024DD967136
380 shares@ €1.840.4% of flowActionHors plateforme de négociation2024DD967138
22,859 shares@ €3.302.0% of flowActionEuronext Growth Paris2023DD887728
173,499 shares@ €0.991591.8% of flowActionEuronext Growth Paris2022DD874066
Ideal exit: 26 Aug 2023 (T+270)
3,001 shares@ €2.704.3% of flowActionEuronext Growth Paris2022DD869182
1,938 shares@ €2.702.8% of flowActionEuronext Growth Paris2022DD868925
Ideal exit: 25 Jul 2023 (T+270)
9,000 shares0ActionHors plateforme de négociation2022DD868930
Ideal exit: 14 Jul 2023 (T+270)
6,820 shares@ €2.709.9% of flowActionEuronext Growth Paris2022DD867905
25 of 47 declarations
About CROSSJECT
CROSSJECT is a French specialty pharmaceutical company listed on Euronext Growth Paris under ticker ALCJ and ISIN FR0011716265. Founded in 2001 by Patrick Alexandre and headquartered in Dijon, the company has built its strategy around a clear mission: to develop easy-to-use, fast and reliable self-administration solutions for emergency medicines. Its core asset is ZENEO®, a proprietary needle-free, pre-filled, single-use auto-injector designed to enable intramuscular delivery by untrained patients, caregivers or healthcare professionals in critical situations. CROSSJECT’s business model is that of an innovation-driven biopharmaceutical company focused on niche emergency-care markets. The lead program is ZEPIZURE®, an emergency treatment for epileptic seizures, alongside other development priorities such as anaphylactic shock and acute adrenal insufficiency. The company also states that it is working on additional products for other life-threatening conditions where immediate drug delivery is essential. This positioning gives CROSSJECT exposure to unmet medical needs rather than broad primary-care competition, which can create strategic differentiation if regulatory and commercial milestones are achieved. A major part of the investment case lies in regulatory and industrial progress. CROSSJECT says it is in advanced regulatory development for ZEPIZURE® and has secured a $60 million contract with BARDA, the U.S. Biomedical Advanced Research and Development Authority. The company notes that the total value of the agreement could reach $155 million if all options are exercised. This relationship is important because it supports development, regulatory work and the potential initial delivery into the U.S. Strategic National Stockpile, making the U.S. market a key growth platform. Geographically, CROSSJECT remains anchored in France while expanding its North American footprint, particularly in the United States. The company highlights a dedicated U.S. presence and commercialization ambitions starting with ZEPIZURE®. Its share has been listed since February 28, 2014, and the stock is eligible for PEA and PEA-PME, which is relevant for French retail investors. Notable corporate facts include the company’s long R&D history, the positioning of ZENEO® as a platform protected until 2038 according to company communications, and the publication in March 2026 of full-year 2025 results confirming a strengthening operational, industrial and financial trajectory. Overall, CROSSJECT remains a high-risk, high-upside healthcare small cap, whose valuation depends heavily on execution, regulatory approvals and eventual monetization of its proprietary emergency-care platform.
